S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:LYEL

Lyell Immunopharma (LYEL) Stock Price, News & Analysis

$2.23
+0.19 (+9.31%)
(As of 03/28/2024 ET)
Today's Range
$2.02
$2.26
50-Day Range
$1.71
$3.07
52-Week Range
$1.32
$3.97
Volume
1.18 million shs
Average Volume
1.00 million shs
Market Capitalization
$566.64 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.50

Lyell Immunopharma MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
146.6% Upside
$5.50 Price Target
Short Interest
Bearish
8.91% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.73mentions of Lyell Immunopharma in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.91) to ($0.93) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.80 out of 5 stars

Medical Sector

490th out of 938 stocks

Pharmaceutical Preparations Industry

223rd out of 423 stocks

LYEL stock logo

About Lyell Immunopharma Stock (NASDAQ:LYEL)

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

LYEL Stock Price History

LYEL Stock News Headlines

AI healthcare stock poised for 36,996% growth?
Buy Alert Issued For AI Small Cap Our last two AI stocks jumped 150% and 130%... But we just issued a brand new "buy alert" for a new one...
AI healthcare stock poised for 36,996% growth?
Buy Alert Issued For AI Small Cap Our last two AI stocks jumped 150% and 130%... But we just issued a brand new "buy alert" for a new one...
Lyell Immunopharma Inc (LYEL)
Heather D. Lyell
Why Lyell Immunopharma Shares Are Rising Today
Lyell Immunopharma reports Q3 results
Lyell Immunopharma Shares Up 8% on Cellares Collaboration
See More Headlines
Receive LYEL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lyell Immunopharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/28/2024
Today
3/28/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:LYEL
Fax
N/A
Employees
224
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$5.50
High Stock Price Target
$6.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+158.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$-234,630,000.00
Net Margins
-180,486.14%
Pretax Margin
-180,486.17%

Debt

Sales & Book Value

Annual Sales
$130,000.00
Book Value
$2.60 per share

Miscellaneous

Free Float
193,113,000
Market Cap
$539.96 million
Optionable
Optionable
Beta
-0.50
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Dr. Richard D. Klausner M.D. (Age 72)
    Founder & Executive Chairman
    Comp: $80k
  • Dr. Lynn Seely M.D. (Age 65)
    Ph.D., President, CEO & Director
    Comp: $430.69k
  • Mr. Charles W. Newton (Age 52)
    Chief Financial Officer
    Comp: $1.72M
  • Mr. Stephen J. Hill (Age 54)
    Chief Operating Officer
    Comp: $1.04M
  • Dr. Gary Lee Ph.D. (Age 47)
    Chief Scientific Officer
    Comp: $639.91k
  • Ms. Elizabeth Homans (Age 58)
    Consultant
    Comp: $1.99M
  • Prof. Stanley R. Riddell M.D.
    Founder & Scientific Advisor
  • Dr. Crystal L. Mackall M.D. (Age 63)
    Founder & Scientific Advisor
  • Nellie Dillery
    Director of Accounting
  • Ms. Ellen Rose
    Senior Vice President of Communications & Investor Relations

LYEL Stock Analysis - Frequently Asked Questions

Should I buy or sell Lyell Immunopharma stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Lyell Immunopharma in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" LYEL shares.
View LYEL analyst ratings
or view top-rated stocks.

What is Lyell Immunopharma's stock price target for 2024?

2 Wall Street research analysts have issued 1 year price objectives for Lyell Immunopharma's stock. Their LYEL share price targets range from $5.00 to $6.00. On average, they expect the company's share price to reach $5.50 in the next twelve months. This suggests a possible upside of 146.6% from the stock's current price.
View analysts price targets for LYEL
or view top-rated stocks among Wall Street analysts.

How have LYEL shares performed in 2024?

Lyell Immunopharma's stock was trading at $1.94 at the beginning of 2024. Since then, LYEL shares have increased by 14.9% and is now trading at $2.23.
View the best growth stocks for 2024 here
.

When is Lyell Immunopharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our LYEL earnings forecast
.

How were Lyell Immunopharma's earnings last quarter?

Lyell Immunopharma, Inc. (NASDAQ:LYEL) announced its earnings results on Wednesday, February, 28th. The company reported ($0.20) EPS for the quarter, beating the consensus estimate of ($0.21) by $0.01. The firm earned $0.01 million during the quarter, compared to analysts' expectations of $4.96 million. Lyell Immunopharma had a negative net margin of 180,486.14% and a negative trailing twelve-month return on equity of 32.67%.

When did Lyell Immunopharma IPO?

Lyell Immunopharma (LYEL) raised $425 million in an initial public offering on Thursday, June 17th 2021. The company issued 25,000,000 shares at $16.00-$18.00 per share. Goldman Sachs, BofA Securities, J.P. Morgan and Morgan Stanley served as the underwriters for the IPO.

Who are Lyell Immunopharma's major shareholders?

Lyell Immunopharma's stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (5.40%), Vanguard Group Inc. (5.35%), WuXi AppTec Co. Ltd. (3.25%), Price T Rowe Associates Inc. MD (2.64%), Price T Rowe Associates Inc. MD (2.64%) and Northern Trust Corp (0.59%). Insiders that own company stock include Cathy Friedman and Richard Klausner.
View institutional ownership trends
.

How do I buy shares of Lyell Immunopharma?

Shares of LYEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:LYEL) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners